Ricevi le ultime notizie sulle azioni Viracta Therapeutics con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di VIRX

Ultime notizie per

Viracta Therapeutics

Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The product candidate of the company is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people with organ transplants.

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

AREN

CSTM

EVAX

GDYN

GEAR

VIRX

Le azioni di Constellium, Viracta, Evaxion, Arena e Grid Dynamics mostrano movimenti significativi nella sessione di pre-market di oggi.

Pre-market: 5 titoli da monitorare oggi, 27 dicembre 2024

Viracta Therapeutics Inc

Press Releases

Viracta Therapeutics Announces Reprioritization of Resources to Enhance Focus on Nana-val Development Program in Patients with Relapsed or Refractory EBV-Positive Peripheral T-Cell Lymphoma

Earnings

Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Health Care

Viracta Therapeutics Announces Closure of NAVAL-1 Clinical Trial and Exploration of Strategic Alternatives

Comments

Viracta Therapeutics Notizie sulle azioni

Notizie

Ultime notizie per

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO